曾菊梅，女，博士，四川大學華西公共衛生學院特聘副研究員。
基本介紹
- 中文名：曾菊梅
- 國籍：中國
- 學位/學歷：博士
- 性別：女
基本介紹,學術成就,學習經歷,工作經歷,承擔課程,研究興趣,主持課題,發明專利,獲獎情況,發表論文,
基本介紹
曾鞏己翻道菊梅，女，中共黨員，微生物學博士，四川大學華西公共衛生學匪愚全院特聘副研究員，衛生檢驗與檢疫系專業教師。2012年畢業於華中農業大學生命科學技術學院農業微生物學國家重點實驗室，獲博士學位。研究領域為分枝桿菌的致病機制，耐藥機制及防治策略。
學術成就
主持國家自然科學基金青年基金，四川大學引進人才科研啟動基金等課題。在Nat Commun、PLoS pathog、mBio、Proc Natl Acad Sci U S A、Environ Microbiol、Front Microbiol、J Proteome Res、Antimicrob Agents Chemother等雜誌發表SCI論文近30篇。獲得國家授權專蒸迎臭利6項，獲得教育部科技獎勵二等級1項。
學習經歷
2007年09月-2012年06月，農業微生物學國家重點實驗室,華中農業大學（病原微生物方向，碩博連讀）博士
工作經歷
2012年07月-2014年11月，中國科學院成都生物研究所，助理研究員
2014年12月-2019年07月，哈佛醫學院/波士頓兒童醫院，博士後
2019年07月-至今，四川大學華西公共衛生學院,特聘副研究員
承擔課程
《分子生物學檢驗技術》
研究興趣
曾菊梅博士一直從事結核分枝桿菌的基因網路、耐藥機制及抗結核藥物靶標研究，具備豐富的轉錄組，蛋白質組，磷酸化蛋白質組和脂代謝組學工作經驗。結核病（Tuberculosis, TB）是一種重大傳染性疾病，是傳染病患者的第二大死因，僅次於愛滋病，是世界性的公共衛生學難題。耐藥性結核分枝桿菌的出現和現有抗結核藥物治療周期長及不能有效殺死持續存在於體內的結核微愉分枝桿菌的問題，迫使我們要研發新型抗結核藥物來解決當前結核病防治中存在的問題。為了有效的防治結核病，需進一步地深入研究和了解結核分枝桿菌，對結核分枝桿菌有整體的認知，最終戰勝和消除結核病。針對新靶標研製藥物，才更有可能獲得全新作用機制和全新骨架結構的抗結核藥物，成功繞開耐藥結核的耐藥機制，獲得可有效殺滅耐藥結核的新型藥物。
主持課題
1.國家自然科學基金青定嚷檔年基金項目：枯草芽孢桿菌解聚酶YwtD調節γ-聚谷氨酸鏈長的結構基礎研究
2.四川大學引進人才科研啟動經費： 結核分枝桿菌生存必需基因DUF3349的功能及套用研究
發明專利
1.專利授權號：ZL201110373829.2。專利名稱：一種吡啶類化合物作為抗結核分枝桿菌抑制劑的套用。發明櫃棵懂人：何正國，曾菊梅，崔濤。授權日期：2014年05月14日。
2.專利授權號：ZL201110373871.4。專利名稱：一種疊氮噻吩類化合物作為抗結核分枝桿菌抑制劑的套用。發明人：何正國，曾菊梅，崔濤。授權日期：2014年05月14日。
3.專利授權號：ZL201110373878.6。專利名稱：一種三嗪類化合物作為抗結核分枝桿菌抑制劑的套用。發明人：何正國，崔濤，曾菊梅。授權日期：2014年06月18日。
4．專利授權號：ZL201110373945.4。專利名稱：一種吡唑類化合物作為抗結核分枝桿菌抑制劑的套用。發明人：何正國，崔濤，曾菊梅。授權日期：2014年06月18日。
5．專利授權號：ZL201110373851.7。專利名稱：一種喹喔啉類化合物作為抗結核分枝桿菌抑制劑的應剃備設捆用。發明人：何正國，崔濤，曾菊梅。授權日期：2014年12月03日。
6．專利授權號：ZL201110373810.8。專利名稱：抗結核抑制劑篩選的靶標基因Rv2780及套用。發明人：何正國，曾菊梅，崔濤。授權日期：2015年11月11日。
獲獎情況
2013年教育部高等學校科學研究優秀成果獎（科學技術）自然科學獎二等獎：結核分枝桿菌細胞生長和耐藥調控網路研究（第八）。
發表論文
1. Toxin-mediatedribosome stalling reprograms theMycobacterium tuberculosis proteome. Barth VC,Zeng J, Vvedenskaya IO, Ouyang M, Husson RN and Woychik NA*. Nat Commun.2019. (12.353)
2. Protein kinases PknA and PknB independently and coordinately regulate essential Mycobacterium tuberculosis physiologies and antimicrobial susceptibility.Zeng J, Platig J, Cheng TY, Ahmed S, Skaf Y, Schwartz D, Steen H, Moody DB, Husson RN*. PLoS pathog. 2020 (6.158)
3. Accurate target identification for Mycobacterium tuberculosis endoribonuclease toxins requires expression in their native host. Cintrón M,Zeng J, Barth VC, Cruz J, Husson RN, and Woychik NA*. Sci Rep. 2019. (4.122)
4. Global Analysis of Lysine Succinylome in the Periodontal Pathogen Porphyromonas gingivalis. Wu L, Gong T, Zhou X,Zeng J, Huang R, Wu Y, Li Y*. Mol Oral Microbiol. 2019. (2.853)
5. A GntR Family Transcription Factor in Streptococcus mutans Regulates Biofilm Formation and Expression of Multiple Sugar Transporter Genes. Li Z, Xiang Z,Zeng J, Li Y, Li J* Front Microbiol. 2019. (4.076)
6. EzrA, a cell shape regulator contributing to biofilm formation and competitiveness in Streptococcus mutans. Xiang Z, Li Z, Ren Z,Zeng J, Peng X, Li Y, Li J. Mol Oral Microbiol. 2019. (2.853)
7. Regulation of Cell Division in Streptococci: Comparing with the Model Rods. Xiang Z, Li Z,Zeng J, Li Y, Li J. Curr Issues Mol Biol. 2019. (2.511)
8. Deletion of cas3 gene in Streptococcus mutans affects biofilm formation and increases fluoride sensitivity. Tang B, Gong T, Zhou X, Lu M,Zeng J, Peng X, Wang S, Li Y. Arch Oral Biol. 2019. (1.549)
9. Novel drug resistance and gene transfer mechanisms in oral bacteria. Jiang S#,Zeng J#, Zhou X, Li Y*. J Dent Res. 2018 (4.602)
10. Interaction between rpsL and gyrA mutations affects the fitness and dual-resistance of Mycobacterium tuberculosis clinical isolates against streptomycin and fluoroquinolone. Sun H#,Zeng J#, Li S, Liang P, Zheng C, Liu Y, Luo T, Rastogi N, Sun Q*. Infect Drug Resist. 2018. (3.779)
11. Solution scattering study of the Bacillus subtilis PgdS enzyme involved in poly-γ-glutamic acids degradation.Zeng J, Jin Y, Liu Z*. PLoS One. 2018. (2.806)
12. Anti-tuberculosis drug target discovery by targeting the higher in-degree proteins (HidPs) of the pathogen’s transcriptional network. Cui T#, Zeng J#, He ZG*. J Tuberc 2018 (New Journal)
13. Genome editing in Streptococcus mutans through self-targeting CRISPR arrays. Gong T, Tang B, Zhou X,Zeng J, Lu M, Guo X, Peng X, Lei L, Gong B, Li Y*. Mol Oral Microbiol.2018. (2.853)
14. Inhibition of Enterococcus faecalis Growth and Biofilm Formation by Molecule Targeting Cyclic di-AMP Synthetase Activity. Chen L, Li X, Zhou X,Zeng J, Ren Z, Lei L, Kang D, Zhang K, Zou J, Li Y*. J Endod. 2018. (2.886)
15. Multi-systems analysis of Mycobacterium tuberculosis reveals kinase-dependent remodeling of the pathogen-environment interface. Carette X, Platig J, Young DC, Helmel M, Young AT, Wang Z, Potluri LP, Moody CS,Zeng J, Prisic S, Paulson JN, Madduri AVR, Mayfield JA, Locher C, Wang T, Quackenbush J, Rhee KY, Moody DB, Steen H, Husson RN*. mBio. 2018. (6.875)
16. Phosphate is the third nutrient monitored by TOR in Candida albicans. Liu N, Flanagan P,Zeng J, Jani N, Cardenas ME, Moran GP, Köhler JR*. Proc Natl Acad Sci U S A. 2017. (9.661)
17. Regulation of oxidative response and extracellular polysaccharide synthesis by a diadenylate cyclase in Streptococcus mutans. Cheng X, Zheng X, Zhou X,Zeng J, Ren Z, Xu X, Cheng L, Li M, Li J, Li Y*. Environ Microbiol. 2016. (5.932)
18. Inhibition of Streptococcus mutans biofilm formation, extracellular polysaccharide production, and virulence by an oxazole derivative. Chen L, Ren Z, Zhou X,Zeng J, Zou J, Li Y*. Appl Microbiol Biotechnol. 2016. (3.376)
19. Molecule Targeting Glucosyltransferase Inhibits Streptococcus mutans Biofilm Formation and Virulence. Ren Z, Cui T,Zeng J, Chen L, Zhang W, Xu X, Cheng L, Li M, Li J, Zhou X, Li Y*. Antimicrob Agents Chemother. 2015. (4.476)
20. A genome-wide regulator-DNA interaction network in the human pathogen Mycobacterium tuberculosis H37Rv.Zeng J#, Cui T#, He ZG*. J Proteome Res. 2012. (5.113)
21. A novel high-throughput B1H-ChIP method for efficiently validating and screening specific regulator-target promoter interactions.Zeng J, Li Y, Zhang S, He ZG*. Appl Microbiol Biotechnol. 2012. (3.425)
22. A New Bacterial Co-expression System for Over-expressing Soluble Protein and Validating Protein-protein Interaction.Zeng J, He ZG*. Methods Mol Biol. 2012.
23. Over-producing soluble protein complex and validating protein-protein interaction through a new bacterial co-expression system.Zeng J, Zhang L, Li Y, Wang Y, Wang M, Duan X, He ZG*. Protein Expr Purif. 2010. (1.563)
24. Novel Antigenic Proteins in Mycobacterium tuberculosis toward Diagnostic and Vaccine Development. Li Y,Zeng J, Shi J, Wang M, Rao M, Xue C, Du Y, He ZG*. J Proteome Res.2010. (5.132)
25. The characterization of conserved binding motifs and potential target genes for M. tuberculosis MtrAB reveals a link between the two-component system and the drug resistance of M. smegmatis. Li Y,Zeng J, Zhang H, He ZG*. BMC Microbiol. 2010. (2.890)
26. Characterization of a functional C-terminus of the Mycobacterium tuberculosis MtrA responsible for both DNA binding and interaction with its two-component partner protein, MtrB. Li Y,Zeng J, He ZG*. J Biochem. 2010. (1.945)
27. A Global Protein-protein Interaction Network in the Human Pathogen Mycobacterium tuberculosis H37Rv. Wang Y, Cui T, Zhang C, Yang M, Huang Y, Li W, Zhang L, Gao C, He Y, Li Y, Huang F,Zeng J, Huang C, Yang Q, Tian Y, Zhao C, Chen H, Zhang H, He ZG*. J Proteome Res. 2010. (5.132)
5．專利授權號：ZL201110373851.7。專利名稱：一種喹喔啉類化合物作為抗結核分枝桿菌抑制劑的套用。發明人：何正國，崔濤，曾菊梅。授權日期：2014年12月03日。
6．專利授權號：ZL201110373810.8。專利名稱：抗結核抑制劑篩選的靶標基因Rv2780及套用。發明人：何正國，曾菊梅，崔濤。授權日期：2015年11月11日。
獲獎情況
2013年教育部高等學校科學研究優秀成果獎（科學技術）自然科學獎二等獎：結核分枝桿菌細胞生長和耐藥調控網路研究（第八）。
發表論文
1. Toxin-mediatedribosome stalling reprograms theMycobacterium tuberculosis proteome. Barth VC,Zeng J, Vvedenskaya IO, Ouyang M, Husson RN and Woychik NA*. Nat Commun.2019. (12.353)
2. Protein kinases PknA and PknB independently and coordinately regulate essential Mycobacterium tuberculosis physiologies and antimicrobial susceptibility.Zeng J, Platig J, Cheng TY, Ahmed S, Skaf Y, Schwartz D, Steen H, Moody DB, Husson RN*. PLoS pathog. 2020 (6.158)
3. Accurate target identification for Mycobacterium tuberculosis endoribonuclease toxins requires expression in their native host. Cintrón M,Zeng J, Barth VC, Cruz J, Husson RN, and Woychik NA*. Sci Rep. 2019. (4.122)
4. Global Analysis of Lysine Succinylome in the Periodontal Pathogen Porphyromonas gingivalis. Wu L, Gong T, Zhou X,Zeng J, Huang R, Wu Y, Li Y*. Mol Oral Microbiol. 2019. (2.853)
5. A GntR Family Transcription Factor in Streptococcus mutans Regulates Biofilm Formation and Expression of Multiple Sugar Transporter Genes. Li Z, Xiang Z,Zeng J, Li Y, Li J* Front Microbiol. 2019. (4.076)
6. EzrA, a cell shape regulator contributing to biofilm formation and competitiveness in Streptococcus mutans. Xiang Z, Li Z, Ren Z,Zeng J, Peng X, Li Y, Li J. Mol Oral Microbiol. 2019. (2.853)
7. Regulation of Cell Division in Streptococci: Comparing with the Model Rods. Xiang Z, Li Z,Zeng J, Li Y, Li J. Curr Issues Mol Biol. 2019. (2.511)
8. Deletion of cas3 gene in Streptococcus mutans affects biofilm formation and increases fluoride sensitivity. Tang B, Gong T, Zhou X, Lu M,Zeng J, Peng X, Wang S, Li Y. Arch Oral Biol. 2019. (1.549)
9. Novel drug resistance and gene transfer mechanisms in oral bacteria. Jiang S#,Zeng J#, Zhou X, Li Y*. J Dent Res. 2018 (4.602)
10. Interaction between rpsL and gyrA mutations affects the fitness and dual-resistance of Mycobacterium tuberculosis clinical isolates against streptomycin and fluoroquinolone. Sun H#,Zeng J#, Li S, Liang P, Zheng C, Liu Y, Luo T, Rastogi N, Sun Q*. Infect Drug Resist. 2018. (3.779)
11. Solution scattering study of the Bacillus subtilis PgdS enzyme involved in poly-γ-glutamic acids degradation.Zeng J, Jin Y, Liu Z*. PLoS One. 2018. (2.806)
12. Anti-tuberculosis drug target discovery by targeting the higher in-degree proteins (HidPs) of the pathogen’s transcriptional network. Cui T#, Zeng J#, He ZG*. J Tuberc 2018 (New Journal)
13. Genome editing in Streptococcus mutans through self-targeting CRISPR arrays. Gong T, Tang B, Zhou X,Zeng J, Lu M, Guo X, Peng X, Lei L, Gong B, Li Y*. Mol Oral Microbiol.2018. (2.853)
14. Inhibition of Enterococcus faecalis Growth and Biofilm Formation by Molecule Targeting Cyclic di-AMP Synthetase Activity. Chen L, Li X, Zhou X,Zeng J, Ren Z, Lei L, Kang D, Zhang K, Zou J, Li Y*. J Endod. 2018. (2.886)
15. Multi-systems analysis of Mycobacterium tuberculosis reveals kinase-dependent remodeling of the pathogen-environment interface. Carette X, Platig J, Young DC, Helmel M, Young AT, Wang Z, Potluri LP, Moody CS,Zeng J, Prisic S, Paulson JN, Madduri AVR, Mayfield JA, Locher C, Wang T, Quackenbush J, Rhee KY, Moody DB, Steen H, Husson RN*. mBio. 2018. (6.875)
16. Phosphate is the third nutrient monitored by TOR in Candida albicans. Liu N, Flanagan P,Zeng J, Jani N, Cardenas ME, Moran GP, Köhler JR*. Proc Natl Acad Sci U S A. 2017. (9.661)
17. Regulation of oxidative response and extracellular polysaccharide synthesis by a diadenylate cyclase in Streptococcus mutans. Cheng X, Zheng X, Zhou X,Zeng J, Ren Z, Xu X, Cheng L, Li M, Li J, Li Y*. Environ Microbiol. 2016. (5.932)
18. Inhibition of Streptococcus mutans biofilm formation, extracellular polysaccharide production, and virulence by an oxazole derivative. Chen L, Ren Z, Zhou X,Zeng J, Zou J, Li Y*. Appl Microbiol Biotechnol. 2016. (3.376)
19. Molecule Targeting Glucosyltransferase Inhibits Streptococcus mutans Biofilm Formation and Virulence. Ren Z, Cui T,Zeng J, Chen L, Zhang W, Xu X, Cheng L, Li M, Li J, Zhou X, Li Y*. Antimicrob Agents Chemother. 2015. (4.476)
20. A genome-wide regulator-DNA interaction network in the human pathogen Mycobacterium tuberculosis H37Rv.Zeng J#, Cui T#, He ZG*. J Proteome Res. 2012. (5.113)
21. A novel high-throughput B1H-ChIP method for efficiently validating and screening specific regulator-target promoter interactions.Zeng J, Li Y, Zhang S, He ZG*. Appl Microbiol Biotechnol. 2012. (3.425)
22. A New Bacterial Co-expression System for Over-expressing Soluble Protein and Validating Protein-protein Interaction.Zeng J, He ZG*. Methods Mol Biol. 2012.
23. Over-producing soluble protein complex and validating protein-protein interaction through a new bacterial co-expression system.Zeng J, Zhang L, Li Y, Wang Y, Wang M, Duan X, He ZG*. Protein Expr Purif. 2010. (1.563)
24. Novel Antigenic Proteins in Mycobacterium tuberculosis toward Diagnostic and Vaccine Development. Li Y,Zeng J, Shi J, Wang M, Rao M, Xue C, Du Y, He ZG*. J Proteome Res.2010. (5.132)
25. The characterization of conserved binding motifs and potential target genes for M. tuberculosis MtrAB reveals a link between the two-component system and the drug resistance of M. smegmatis. Li Y,Zeng J, Zhang H, He ZG*. BMC Microbiol. 2010. (2.890)
26. Characterization of a functional C-terminus of the Mycobacterium tuberculosis MtrA responsible for both DNA binding and interaction with its two-component partner protein, MtrB. Li Y,Zeng J, He ZG*. J Biochem. 2010. (1.945)
27. A Global Protein-protein Interaction Network in the Human Pathogen Mycobacterium tuberculosis H37Rv. Wang Y, Cui T, Zhang C, Yang M, Huang Y, Li W, Zhang L, Gao C, He Y, Li Y, Huang F,Zeng J, Huang C, Yang Q, Tian Y, Zhao C, Chen H, Zhang H, He ZG*. J Proteome Res. 2010. (5.132)
